First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study
16.3.2021 14:03:00 EET | Business Wire | Press release
Veeva Systems (NYSE: VEEV) today announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center. Veeva eConsent is the first validated application for sites and patients that transforms the consent process from manual and paper-based to an end-to-end digital experience. Patients can review documents and protocols and provide consent via mobile phone, streamlining the experience for both patients and sites.
“As one of the first sites using Veeva eConsent, we’re excited to collaborate with Veeva to help the industry shift from paper to digital consent for the benefit of patients and clinical research,” said Charles Sydnor, CCRA, ACRP-CP, project manager at Crofoot Research Center. “Veeva eConsent makes the process easy for our patients and allows us to break down the barriers of paper and location, expanding the reach of our study.”
COVID-19 accelerated the industry’s move to digital solutions that enable decentralized trials and keep studies on track, speed study start-up, and improve trial execution. Veeva eConsent enables this transformation through digital consent document creation, approval, and exchange. Sites can use the application for trials across sponsors and automate the flow of consent documents to the investigator site file (ISF) for better collaboration and greater speed.
With Veeva eConsent, sponsors get real-time visibility into patient consent status, date, and version and monitors and site personnel gain remote access to trial information. Reducing the time spent on administrative tasks increases site and patient engagement throughout a study.
“In just six months, we went from concept to the first patient using Veeva eConsent,” said Tim Davis, vice president, MyVeeva for Patients at Veeva Systems. “This marks a major step forward for the future of paperless, patient-centric trials and we remain focused on continuing to deliver innovations that will help the industry realize this important vision.”
Attend the upcoming webinar on April 29 to hear Crofoot discuss how Veeva eConsent helps sites run more efficient clinical trials and to learn more about Veeva Clinical Network, the industry’s only solution that connects sponsors, sites, and patients to accelerate clinical research.
Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 975 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com/eu.
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
© 2021 Veeva Systems Inc. All rights reserved. Veeva, V, Vault and Crossix are registered trademarks of Veeva Systems Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005107/en/
Contact information
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UAE Commits $49bn to Local Manufacturers7.5.2026 17:00:00 EEST | Press release
The United Arab Emirates (UAE) pledged $49 billion in industrial procurement opportunities on Monday and announced plans to localize more than 5,000 products as the Gulf state doubled down on its industrial sovereignty agenda. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507855698/en/ UAE commits $49bn to local manufacturers (Photo: AETOSWire) Dr. Sultan Al Jaber, UAE Minister of Industry and Advanced Technology, made the announcement at the opening of the fifth edition of Make it in the Emirates, which follows a period that has tested the region. “History remembers the challenges nations face. But it also remembers how nations respond to them and what they build next,” he said. TA’ZIZ announced $40.5 billion worth of agreements aimed at expanding UAE chemical production capacity. The opportunities include offtakes and $2 billion of financing for the UAE’s first world-scale methanol plant. A $270 million National Indust
Andersen Consulting Strengthens Organizational Transformation Capabilities with Afiniti7.5.2026 16:30:00 EEST | Press release
Andersen Consulting announces a Collaboration Agreement with Afiniti, a global business transformation consultancy headquartered in the United Kingdom that helps organizations deliver and sustain complex change programs. Founded in 2003, Afiniti is a global business change consultancy based in the UK and U.S., supporting clients through complex transformation across people, process, systems, and data, and bringing change to life through creative consulting services. The firm primarily serves highly regulated, safety-driven, and asset-intensive organizations with large, geographically dispersed workforces across sectors including energy, utilities, life sciences, transport, and construction. Afiniti works with well-known brands to deliver end-to-end expertise across organizational, digital and AI, cultural, and operating model transformation, particularly in complex scenarios such as mergers and acquisitions, large-scale technology adoption, and underperforming change programs that have
Datavault AI Announces Board of Directors Has Requested Management’s Complete Plan for Dividend Spin-Out of Acoustic Sciences Division into Stand-Alone Public Company7.5.2026 16:07:00 EEST | Press release
Datavault AI Inc. (“Datavault AI” or the “Company”) (NASDAQ:DVLT), a pioneering technology licensing company seeking to redefine data valuation, monetization, and secure Web 3.0 experiences, today announced that Company management has commenced its evaluation of a potential dividend spin-out of the Company’s Acoustic Sciences division which includes its ADIO®, WiSA®, Event Citadel™, and API Media operations into a new stand-alone public company, which is proposed to be named “API Media”. The Company has reserved the ticker symbol “ADIO” for the proposed spin-out entity and currently intends that API Media will be listed on NASDAQ following completion of the proposed transactions, which remain subject to approval by the Company’s board of directors, definitive agreement, and satisfaction of closing conditions, as well as any regulatory approvals that may be required in connection therewith. The Company has engaged Houlihan Lokey as its financial advisor and Paul Hastings LLP as its lega
Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura ® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis7.5.2026 15:50:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). These data were presented (Abstract ID: P0851) today at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium, being held May 7–9, 2026, in Athens, Greece. As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on Opzelura versus vehicle cream achieving EASI75 (≥75% improvement in Eczema Area and Severity Index score from baseline) and, separately, IGA-TS (Investigator's Global Assessment Treatment Success, defined as an IGA score of 0 [clear] or 1 [almost clear] with at least a two-point improvement from baseline).1 Patients who
Rapid Medical™’s TIGERTRIEVER™ 13 Demonstrates Promising 90-Day Outcomes in DISTALS Trial, Reinforcing Pivotal Safety and Efficacy Findings7.5.2026 15:03:00 EEST | Press release
Rapid Medical™, a leading developer of advanced stroke treatment devices, today announced full results from the DISTALS randomized clinical trial, presented at the 11th European Stroke Organisation Conference (ESOC) in Maastricht, Netherlands, showing that TIGERTRIEVER™ 13 can safely restore blood flow to the brain and may improve clinical outcomes in patients with distal and medium vessel occlusion (DMVO) stroke. These findings build on earlier results showing a threefold improvement in restoring blood flow compared with medical management alone (p<0.0001), with no cases of serious brain bleeding observed in the treatment group. “These results show we can now safely restore blood flow and suggest this will make a meaningful difference for the right patients,” said Jeffrey L. Saver, MD, UCLA, and Principal Investigator of DISTALS. “What’s important is that both the device and the trial were designed specifically for distal stroke. By using a device built for these small vessels and mea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom